Recent positive Phase 3 trial results for the companies' jointly developed mRNA cancer vaccine in melanoma underscore their ongoing strategic collaboration without any merger signals, reinforcing trader consensus that no acquisition will be announced this year. Merck's separate equity stake in Moderna and both firms' independent share-price reactions to the data further signal partnership continuity rather than consolidation. Market-implied odds near 99% reflect this established dynamic, with historical precedents of similar biotech alliances rarely escalating to full deals absent major catalysts. Tail risks remain limited but could include unexpected regulatory or financial pressures prompting a strategic shift before year-end.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · AggiornatoSì
1% probabilità
NUOVO
NUOVO
31 dic 2026
Sì
1% probabilità
NUOVO
NUOVO
31 dic 2026
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Recent positive Phase 3 trial results for the companies' jointly developed mRNA cancer vaccine in melanoma underscore their ongoing strategic collaboration without any merger signals, reinforcing trader consensus that no acquisition will be announced this year. Merck's separate equity stake in Moderna and both firms' independent share-price reactions to the data further signal partnership continuity rather than consolidation. Market-implied odds near 99% reflect this established dynamic, with historical precedents of similar biotech alliances rarely escalating to full deals absent major catalysts. Tail risks remain limited but could include unexpected regulatory or financial pressures prompting a strategic shift before year-end.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Mercato aperto: Aug 19, 2026, 3:58 PM ET
Volume
$425Data di fine
31 dic 2026Mercato aperto
Aug 19, 2026, 3:58 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Recent positive Phase 3 trial results for the companies' jointly developed mRNA cancer vaccine in melanoma underscore their ongoing strategic collaboration without any merger signals, reinforcing trader consensus that no acquisition will be announced this year. Merck's separate equity stake in Moderna and both firms' independent share-price reactions to the data further signal partnership continuity rather than consolidation. Market-implied odds near 99% reflect this established dynamic, with historical precedents of similar biotech alliances rarely escalating to full deals absent major catalysts. Tail risks remain limited but could include unexpected regulatory or financial pressures prompting a strategic shift before year-end.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Volume
$425Data di fine
31 dic 2026Mercato aperto
Aug 19, 2026, 3:58 PM ETResolver
0x65070BE91...Recent positive Phase 3 trial results for the companies' jointly developed mRNA cancer vaccine in melanoma underscore their ongoing strategic collaboration without any merger signals, reinforcing trader consensus that no acquisition will be announced this year. Merck's separate equity stake in Moderna and both firms' independent share-price reactions to the data further signal partnership continuity rather than consolidation. Market-implied odds near 99% reflect this established dynamic, with historical precedents of similar biotech alliances rarely escalating to full deals absent major catalysts. Tail risks remain limited but could include unexpected regulatory or financial pressures prompting a strategic shift before year-end.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato
Fai attenzione ai link esterni.
Fai attenzione ai link esterni.
Domande frequenti